IPL 512602

Drug Profile

IPL 512602

Alternative Names: AVE 0547; IPL 512,602

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma

Most Recent Events

  • 07 Feb 2017 Discontinued - Phase-II for Asthma in Russia, Ukraine, Eastern Europe, USA (PO)
  • 07 Feb 2017 Discontinued - Preclinical for Allergic rhinitis in North America (PO)
  • 29 Jan 2007 Inflazyme completes the phase IIb CAPSICS trial for Asthma in the US, Eastern Europe, Russia and Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top